Tables
Table 4. Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections
This table lists the known, predicted, or suspected pharmacokinetic (PK) interactions between drugs used for the treatment or prevention of HIV-associated opportunistic infections (OIs). Many of the drugs listed in this table may also interact with antiretroviral (ARV) drugs. Clinicians should see the Drug–Drug Interactions tables in the most current Adult and Adolescent Antiretroviral Guidelines to assess interaction potentials between OI drugs and ARV drugs.
Throughout the table, three recommendations are commonly used when concomitant administration of two drugs may lead to untoward consequences. The rationales for these recommendations are summarized below:
Do not coadminister.
There is either strong evidence or strong likelihood that the PK interaction cannot be managed with a dose modification of one or both drugs and will or may result in either—
- Increase in concentrations of one or both drugs, which may lead to excessive risk of toxicity; or
- Decrease in concentrations of one or both drugs, which may render one or both drugs ineffective.
Coadministration should be avoided, if possible.
There is a potential for significant PK interactions. If other more favorable options exist, clinicians are advised to consider changing components of the regimen to accommodate a safer or more effective regimen. However, coadministration of the drugs may be necessary when there are no other acceptable therapeutic options that provide a more favorable benefit-to-risk ratio. Therapeutic drug monitoring, if available, may facilitate any necessary dose adjustments.
Use with caution.
Drug combinations are recommended to be used with caution when—
- PK studies have shown a moderate degree of interaction of unknown clinical significance; or
- Based on the known metabolic pathway of the two drugs, there is a potential for PK interaction of unknown clinical significance.
Rifamycin-Related Induction Interactions
Rifamycin antibiotics are potent inducers of Phase 1 and Phase 2 drug metabolizing reactions. They also affect various transporters. When a rifamycin antibiotic must be combined with an interacting drug, close monitoring for clinical efficacy of the coadministered agent is advised. Therapeutic drug monitoring, if available, may facilitate any necessary dose adjustments.
- Rifampin (also known as rifampicin): Interactions may not be apparent in the first several days of rifampin therapy. However, with daily doses of rifampin, enzyme induction increases over a week or more. Based on limited data, larger daily doses of rifampin (e.g., 1,200 mg or more) appear to produce the same maximum induction as lower doses, but the induction effect occurs more rapidly.
- Rifabutin: In general, rifabutin as a cytochrome P450 3A4 (CYP3A4) inducer is about 40% of the potency of rifampin, but this can vary by substrate and enzymatic reaction. Rifabutin is also a substrate of CYP3A4 and may be subject to changes in drug exposure when given concomitantly with 3A4 inhibitors or inducers. Rifabutin dosage modification, therapeutic drug monitoring, and/or more frequent monitoring for rifabutin-related toxicities may be needed.
- Rifapentine: In general, daily rifapentine is at least as potent an inducer as rifampin. However, the potential for drug interactions with once-weekly rifapentine is not well studied. Reduced exposure of concurrent drugs that are CYP3A4 substrates is likely to occur with once-weekly rifapentine, with the extent varying by drug.
Azole- and Macrolide-Related Inhibition Interactions
Azole antifungals, including fluconazole, isavuconazole, itraconazole, posaconazole, and voriconazole, are substrates and potent inhibitors of metabolic pathways, including cytochrome P450 enzymes and/or drug transporters (e.g., p-glycoprotein). Interactions involving azole antifungals are common. When an azole antifungal must be combined with an interacting drug, close monitoring for clinical toxicity and efficacy of the azole and/or the coadministered agent may be needed. Therapeutic drug monitoring, if available, may facilitate any necessary dose adjustments.
Macrolides have been shown to form complexes with drug-oxidizing enzymes, including cytochrome P450 enzymes, which render an inhibitory effect. In general, erythromycin and clarithromycin are moderate to strong inhibitors, while azithromycin’s propensity for causing clinically relevant drug interactions is lowest, as it does not form complexes with cytochrome P450 enzymes that lead to enzyme inactivation.
Pharmacodynamic Interactions
Pharmacodynamic interactions are not addressed in this table. For example, many of the drug classes listed below independently possess a risk for QTc prolongation, including azoles, macrolides, and certain anti-tuberculosis and antimalarial medications. Coadministration of drugs in these classes may require monitoring for QTc prolongation, particularly in patients with predisposing risk factors.
Therapeutic Drug Monitoring
Drug interactions can alter oral absorption or systemic clearance of drugs. More than one interaction can occur at the same time, with potentially opposing effects. Therapeutic drug monitoring (TDM), if available, may facilitate any necessary dose adjustments in these complicated patients. TDM allows the clinician to make informed, individualized decisions about dose adjustments that are more precise than standardized dose adjustments based upon anticipated, average effects.
Drugs that are marked with an asterisk (*) in the table below are known to have assays (for clinical and/or research purposes) available within the United States and typically in Europe as well. When TDM is appropriate, clinicians should contact their clinical laboratory to determine assay availability and turnaround time for their institution.
Note: To avoid redundancy, drug–drug interactions are listed only once by primary drug (listed alphabetically). Subsequently, when an interacting agent becomes the primary drug, guideline users are referred to the entry for the initial primary drug. See the Clarithromycin row for the first example of this format.
|
Primary Drug |
Interacting Agent |
Effect on Primary and/or Concomitant Drug Concentrations |
Recommendations |
|---|---|---|---|
|
Artemether/ |
Clarithromycin |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. |
|
Erythromycin |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of erythromycin. |
|
|
Fluconazole |
↑ lumefantrine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
|
Isavuconazole |
↑ lumefantrine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
|
Itraconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
|
Mefloquine |
↓ lumefantrine possible |
If mefloquine is administered immediately before artemether/lumefantrine, monitor for decreased efficacy of artemether/lumefantrine and encourage food intake. |
|
|
Posaconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
|
Rifabutina |
↓ artemether, DHA, and lumefantrine expected |
Use with caution. Monitor for antimalarial efficacy. |
|
|
Rifampina |
Artemether AUC ↓ 89% DHA AUC ↓ 85% Lumefantrine AUC ↓ 68% |
Do not coadminister. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ artemether, DHA, and lumefantrine expected |
Do not coadminister. |
|
|
Voriconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
| Atovaquone* |
Doxycycline |
Atovaquone concentration ↓ approximately equal to 40% with tetracycline No interaction study with doxycycline |
Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. |
|
Rifabutina |
Atovaquone Css ↓ 34% Rifabutin Css ↓ 19% |
Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. |
|
|
Rifampina |
Atovaquone Css ↓ 52% Rifampin Css ↑ 37% |
Do not coadminister. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ atovaquone expected |
Do not coadminister. |
|
| Bedaquiline* |
Clarithromycin |
↑ bedaquiline expected |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
|
Erythromycin |
↑ bedaquiline expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Fluconazole |
↑ bedaquiline possible |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
|
Isavuconazole |
↑ bedaquiline possible |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
|
Itraconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. If coadministration is required for >14 days, weigh the benefits of therapy against the risks of bedaquiline toxicities. |
|
|
Posaconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
|
Rifabutina |
↔ bedaquiline ↓ rifabutin possible |
If coadministered, separate time of administration; perform rifabutin TDM and adjust dose accordingly. |
|
|
Rifampina |
Bedaquiline AUC ↓ 53% |
Do not coadminister. |
|
|
Rifapentinea |
Daily Rifapentine Bedaquiline AUC ↓ 55% Weekly Rifapentine ↓ bedaquiline expected |
Do not coadminister. |
|
|
Voriconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
| Brincidofovir |
Clarithromycin |
↑ brincidofovir expected |
Coadministration should be avoided, if possible. If coadministered, postpone clarithromycin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. Consider azithromycin in place of clarithromycin. |
|
Erythromycin |
↑ brincidofovir expected |
Coadministration should be avoided, if possible. If coadministered, postpone erythromycin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. Consider azithromycin in place of erythromycin. |
|
|
Rifampin |
↑ brincidofovir expected |
Coadministration should be avoided, if possible. If coadministered, postpone rifampin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. |
|
| Caspofungin |
Rifabutina |
↓ caspofungin possible |
Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). |
|
Rifampina |
Caspofungin Cmin ↓ 30% |
If coadministered, caspofungin dose should be increased to 70 mg/day. Consider alternative echinocandin (e.g., micafungin or anidulafungin). |
|
|
Rifapentinea |
Daily Rifapentine
Weekly Rifapentine
|
Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). |
|
| Chloroquine* | Clarithromycin |
↑ chloroquine expected |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
|
Erythromycin |
↑ chloroquine expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Fluconazole |
↑ chloroquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
|
Isavuconazole |
↑ chloroquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
|
Itraconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
|
Posaconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
|
Rifabutina |
↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
|
Rifampina |
↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
|
Voriconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
| Clarithromycin* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Fluconazole |
Clarithromycin AUC ↑ 18% and Cmin↑ 33% |
No dose adjustment necessary in patients with normal renal function. Monitor for clarithromycin toxicity. |
|
|
Isavuconazole |
↑ isavuconazole and clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both isavuconazole and clarithromycin. Role of isavuconazole TDM has not been established. |
|
|
Itraconazole |
↑ itraconazole and clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both itraconazole and clarithromycin; perform itraconazole and clarithromycin TDM and adjust dose accordingly. |
|
|
Mefloquine |
↑ mefloquine expected |
Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, monitor for mefloquine toxicity. |
|
|
Posaconazole |
↑ clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. |
|
|
Quinine |
↑ quinine expected ↑ clarithromycin possible |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
|
|
Rifabutina |
Clarithromycin AUC ↓ 44% 14-OH clarithromycin AUC ↑ 57% Rifabutin AUC ↑ 76% to 99% des-Rbt AUC ↑ 375% |
Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, consider reducing rifabutin dose, perform clarithromycin and rifabutin TDM and adjust dose accordingly. Monitor for rifabutin toxicities. |
|
|
Rifampina |
Clarithromycin concentration ↓ 87% Rifampin AUC ↑ 60% |
Do not coadminister. Use azithromycin in place of clarithromycin. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ clarithromycin expected ↑ 14-OH clarithromycin and rifapentine expected |
Daily Rifapentine
Weekly Rifapentine
If coadministered, monitor for rifapentine toxicities and clarithromycin efficacy; perform clarithromycin and rifapentine TDM and adjust doses accordingly. |
|
|
Voriconazole |
↑ clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. |
|
| Dapsone* |
Rifabutina |
Dapsone AUC ↓ 27% to 40% |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
|
Rifampina |
Dapsone concentration ↓ 7-fold to 10-fold and t1/2 ↓ from 24 hours to 11 hours |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ dapsone expected |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
|
| Doxycycline |
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
Rifabutina |
↓ doxycycline possible |
Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
|
Rifampina |
Doxycycline AUC ↓ 59% |
Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
|
Rifapentinea |
Daily Rifapentine
Weekly Rifapentine
|
Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
| Erythromycin |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
| Fluconazole |
↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Isavuconazole |
↑ erythromycin and isavuconazole possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Itraconazole |
Itraconazole AUC ↑ 36% ↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Mefloquine |
↑ mefloquine possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Posaconazole |
↑ erythromycin expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Quinine |
↑ quinine expected ↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
|
Rifabutina |
↓ erythromycin possible ↑ rifabutin possible |
Use with caution. Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy and rifabutin toxicities; perform rifabutin TDM and adjust dose accordingly. |
|
|
Rifampina |
↓ erythromycin expected |
Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ erythromycin expected |
Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. |
|
|
Voriconazole |
↑ erythromycin expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
| Fluconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Mefloquine |
↑ mefloquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
|
Quinine |
↑ quinine expected ↑ fluconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and fluconazole toxicity. |
|
|
Rifabutina |
Rifabutin AUC ↑ 80% ↔ fluconazole expected |
Use with caution. Monitor for rifabutin toxicities. Perform rifabutin TDM; may need to decrease rifabutin dose to 150 mg/day. |
|
|
Rifampina |
Fluconazole AUC ↓ 23% to 56% |
Monitor for antifungal efficacy; may need to increase fluconazole dose. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ fluconazole expected |
Monitor for antifungal efficacy; may need to increase fluconazole dose. |
|
|
Glecaprevir/ Pibrentasvir |
Rifabutina |
↓ glecaprevir and pibrentasvir possible |
Coadministration should be avoided, if possible. Consider alternative agents. |
|
Rifampina |
Glecaprevir AUC ↓ 88% Pibrentasvir AUC ↓ 87% |
Do not coadminister. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ glecaprevir and pibrentasvir expected |
Do not coadminister. Consider alternative agents. |
|
|
TDF |
TFV AUC ↑ 29% when coadministered as EFV/TDF/FTC |
Use usual dose. Monitor renal function or consider TAF. |
|
|
TAF |
↔ TFV concentration when coadministered as EVG/c/TAF/FTC |
No dose adjustment necessary |
|
|
Isavuconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Mefloquine |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
|
Quinine |
↑ quinine expected ↑ isavuconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and isavuconazole toxicities. |
|
|
Rifabutina |
↓ isavuconazole expected ↑ rifabutin expected |
Consider alternative agent(s). If alternative agents are not available, use with close monitoring for isavuconazole antifungal activity and rifabutin toxicity. Perform rifabutin TDM and adjust dose accordingly. |
|
|
Rifampina |
Isavuconazole AUC ↓ 97% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ isavuconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
|
Itraconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Mefloquine |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
|
Quinine |
↑ quinine expected ↑ itraconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and itraconazole toxicities; perform itraconazole TDM and adjust dose accordingly. |
|
|
Rifabutina |
Itraconazole AUC ↓ 70% ↑ rifabutin expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
|
Rifampina |
Itraconazole AUC ↓ 64% to 88% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ itraconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
|
Linezolid* |
Rifabutina |
↓ linezolid possible |
Monitor for linezolid efficacy. |
|
Rifampina |
Linezolid AUC ↓ 32% |
Monitor for linezolid efficacy. Perform linezolid TDM and adjust dose accordingly. |
|
|
Rifapentinea |
Daily Rifapentine ↓ linezolid expected Weekly Rifapentine ↓ linezolid possible |
Daily Rifapentine Monitor for linezolid efficacy. Perform linezolid TDM and adjust dose accordingly. Weekly Rifapentine Monitor for linezolid efficacy. |
|
|
Mefloquine* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
|
Posaconazole |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
|
Rifabutina |
↓ mefloquine possible |
Monitor for mefloquine efficacy. |
|
|
Rifampina |
Mefloquine AUC ↓ 68% |
Do not coadminister. Use alternative antimalarial drug or rifabutin. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ mefloquine expected |
Do not coadminister. Use alternative antimalarial drug or rifabutin. |
|
|
Voriconazole |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
| Posaconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
| Quinine |
↑ quinine expected ↑ posaconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. |
|
|
Rifabutina |
Posaconazole AUC ↓ 49% Rifabutin AUC ↑ 72% |
Coadministration should be avoided, if possible. If coadministered, perform posaconazole and rifabutin TDM and adjust doses accordingly; monitor for clinical response to posaconazole and rifabutin toxicities. |
|
|
Rifampina |
↓ posaconazole expected |
Do not coadminister when treating invasive fungal infections. If coadministered for treatment of noninvasive fungal infections, perform posaconazole TDM and adjust dose accordingly; monitor for clinical response. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ posaconazole expected |
Daily Rifapentine Do not coadminister when treating invasive fungal infections. If coadministered for treatment of noninvasive fungal infections, perform posaconazole TDM and adjust dose accordingly; monitor for clinical response. Weekly Rifapentine Coadministration should be avoided, if possible. If coadministered, perform posaconazole TDM and adjust dose accordingly; monitor clinical response. |
|
| Quinine* |
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
|
Rifabutina |
↓ quinine possible ↑ rifabutin possible |
Monitor for quinine efficacy. Monitor for rifabutin toxicity. |
|
|
Rifampina |
Quinine AUC ↓ 75% to 85% |
Do not coadminister. |
|
|
Rifapentinea |
Daily and Weekly Rifapentine ↓ quinine expected |
Do not coadminister. |
|
|
Voriconazole |
↑ quinine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. |
|
| Rifabutina* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
|
Quinine |
See Quinine. |
See Quinine. |
|
|
Sofosbuvir/Velpatasvir |
↓ velpatasvir, sofosbuvir expected |
Do not coadminister. |
|
|
TAF |
↓ TAF, TFV, TFV-DP expected ↑ TFV-DP expected versus TDF alone |
If coadministered, monitor for HIV and HBV treatment efficacy. Note: Interpretation extrapolated from TAF and rifampin (see Rifampin). FDA labeling recommends not to coadminister. |
|
|
TDF |
↔ TDF, TFV, TFV-DP expected |
No dosage adjustment necessary. |
|
|
Voriconazole |
Voriconazole AUC ↓ 79% Rifabutin AUC ↑ 4-fold |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). Coadministration may be considered if both voriconazole and rifabutin TDM is available to guide therapy. |
|
| Rifampina* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
|
Quinine |
See Quinine. |
See Quinine. |
|
|
Sofosbuvir/Velpatasvir |
Sofosbuvir AUC ↓ 72% Velpatasvir AUC ↓ 82% |
Do not coadminister. |
|
|
TAF |
TAF Plus Rifampin
Intracellular TFV-DP concentration is 4.2-fold greater than with TDF alone. |
If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. |
|
|
TDF |
TDF Plus Rifampin 600 mg Daily ↔ TFV |
No dosage adjustment necessary |
|
|
Voriconazole |
Voriconazole AUC ↓96% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
| Rifapentinea* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
|
Quinine |
See Quinine. |
See Quinine. |
|
|
TAF |
Daily and Weekly Rifapentine ↓ TAF, TFV, TFV-DP possible |
If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. |
|
|
TDF |
↔ TDF, TFV, TFV-DP expected |
No dosage adjustment necessary |
|
|
Sofosbuvir/Velpatasvir |
↓ sofosbuvir, velpatasvir expected |
Do not coadminister. |
|
|
Voriconazole |
↓ voriconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
| Sofosbuvir*/ Velpatasvir |
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
|
TAF |
TFV AUC ↑ 52% (when RPV/TAF/FTC given with SOF/VEL/VOX) |
No dosage adjustment necessary |
|
|
TDF |
TFV AUC ↑ 35% to 40% (when given with EVG/c/FTC or RPV/FTC) TFV AUC ↑ 81% (when given with EFV/FTC and SOF/VEL) TFV AUC ↑ 39% (when given with DRV/r/FTC and SOF/VEL/VOX) |
Monitor for TDF toxicities. Consider TAF in place of TDF. |
|
| Tenofovir* Alafenamide |
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
|
Sofosbuvir/Velpatasvir |
See Sofosbuvir/Velpatasvir. |
See Sofosbuvir/Velpatasvir. |
|
| Tenofovir* Disoproxil Fumarate |
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
|
Sofosbuvir/Velpatasvir |
See Sofosbuvir/Velpatasvir. |
See Sofosbuvir/Velpatasvir. |
|
| Voriconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
|
Quinine |
See Quinine. |
See Quinine. |
|
|
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
|
a Refer to the subsection Rifamycin-Related Induction Interactions in the Table 4 introduction above. * Drugs marked with asterisk (*) are those which are known to have assays available (for clinical and/or research purposes) within the United States and typically in Europe. When TDM is appropriate, clinicians should contact their clinical laboratory to determine assay availability and turnaround time for their institution. Key to Symbols |
|||
Tables
Table 4. Significant Pharmacokinetic Interactions between Drugs Used to Treat or Prevent Opportunistic Infections
| Primary Drug | Interacting Agent | Effect on Primary and/or Concomitant Drug Concentrations | Recommendations |
|---|---|---|---|
| Artemether/ Lumefantrine | Clarithromycin | ↑ lumefantrine expected | Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. |
| Erythromycin | ↑ lumefantrine expected | Coadministration should be avoided, if possible. Consider azithromycin in place of erythromycin. | |
| Fluconazole | ↑ lumefantrine possible | Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. | |
| Isavuconazole | ↑ lumefantrine possible | Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. | |
| Itraconazole | ↑ lumefantrine expected | Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. | |
| Mefloquine | ↓ lumefantrine possible | If mefloquine is administered immediately before artemether/lumefantrine, monitor for decreased efficacy of artemether/lumefantrine and encourage food intake. | |
| Posaconazole | ↑ lumefantrine expected | Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. | |
| Rifabutina | ↓ artemether, DHA, and lumefantrine expected | Use with caution. Monitor for antimalarial efficacy. | |
| Rifampina | Artemether AUC ↓ 89% DHA AUC ↓ 85% Lumefantrine AUC ↓ 68% | Do not coadminister. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ artemether, DHA, and lumefantrine expected | Do not coadminister. | |
| Voriconazole | ↑ lumefantrine expected | Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. | |
| Atovaquone* | Doxycycline | Atovaquone concentration ↓ approximately equal to 40% with tetracycline No interaction study with doxycycline | Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. |
| Rifabutina | Atovaquone Css ↓ 34% Rifabutin Css ↓ 19% | Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. | |
| Rifampina | Atovaquone Css ↓ 52% Rifampin Css ↑ 37% | Do not coadminister. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ atovaquone expected | Do not coadminister. | |
| Bedaquiline* | Clarithromycin | ↑ bedaquiline expected | Do not coadminister. Consider azithromycin in place of clarithromycin. |
| Erythromycin | ↑ bedaquiline expected | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Fluconazole | ↑ bedaquiline possible | Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. | |
| Isavuconazole | ↑ bedaquiline possible | Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. | |
| Itraconazole | ↑ bedaquiline expected | Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. If coadministration is required for >14 days, weigh the benefits of therapy against the risks of bedaquiline toxicities. | |
| Posaconazole | ↑ bedaquiline expected | Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. | |
| Rifabutina | ↔ bedaquiline ↓ rifabutin possible | If coadministered, separate time of administration; perform rifabutin TDM and adjust dose accordingly. | |
| Rifampina | Bedaquiline AUC ↓ 53% | Do not coadminister. | |
| Rifapentinea | Daily Rifapentine Bedaquiline AUC ↓ 55% Weekly Rifapentine ↓ bedaquiline expected | Do not coadminister. | |
| Voriconazole | ↑ bedaquiline expected | Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. | |
| Brincidofovir | Clarithromycin | ↑ brincidofovir expected | Coadministration should be avoided, if possible. If coadministered, postpone clarithromycin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. Consider azithromycin in place of clarithromycin. |
| Erythromycin | ↑ brincidofovir expected | Coadministration should be avoided, if possible. If coadministered, postpone erythromycin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. Consider azithromycin in place of erythromycin. | |
| Rifampin | ↑ brincidofovir expected | Coadministration should be avoided, if possible. If coadministered, postpone rifampin for at least 3 hours after brincidofovir and monitor for brincidofovir toxicities. | |
| Caspofungin | Rifabutina | ↓ caspofungin possible | Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). |
| Rifampina | Caspofungin Cmin ↓ 30% | If coadministered, caspofungin dose should be increased to 70 mg/day. Consider alternative echinocandin (e.g., micafungin or anidulafungin). | |
| Rifapentinea | Daily Rifapentine
Weekly Rifapentine
| Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). | |
| Chloroquine* | Clarithromycin | ↑ chloroquine expected | Do not coadminister. Consider azithromycin in place of clarithromycin. |
| Erythromycin | ↑ chloroquine expected | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Fluconazole | ↑ chloroquine possible | Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. | |
| Isavuconazole | ↑ chloroquine possible | Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. | |
| Itraconazole | ↑ chloroquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. | |
| Posaconazole | ↑ chloroquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. | |
| Rifabutina | ↓ chloroquine expected | Monitor for chloroquine efficacy. | |
| Rifampina | ↓ chloroquine expected | Monitor for chloroquine efficacy. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ chloroquine expected | Monitor for chloroquine efficacy. | |
| Voriconazole | ↑ chloroquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. | |
| Clarithromycin* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Fluconazole | Clarithromycin AUC ↑ 18% and Cmin↑ 33% | No dose adjustment necessary in patients with normal renal function. Monitor for clarithromycin toxicity. | |
| Isavuconazole | ↑ isavuconazole and clarithromycin expected | Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both isavuconazole and clarithromycin. Role of isavuconazole TDM has not been established. | |
| Itraconazole | ↑ itraconazole and clarithromycin expected | Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both itraconazole and clarithromycin; perform itraconazole and clarithromycin TDM and adjust dose accordingly. | |
| Mefloquine | ↑ mefloquine expected | Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, monitor for mefloquine toxicity. | |
| Posaconazole | ↑ clarithromycin expected | Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. | |
| Quinine | ↑ quinine expected ↑ clarithromycin possible | Do not coadminister. Consider azithromycin in place of clarithromycin. | |
| Rifabutina | Clarithromycin AUC ↓ 44% 14-OH clarithromycin AUC ↑ 57% Rifabutin AUC ↑ 76% to 99% des-Rbt AUC ↑ 375% | Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, consider reducing rifabutin dose, perform clarithromycin and rifabutin TDM and adjust dose accordingly. Monitor for rifabutin toxicities. | |
| Rifampina | Clarithromycin concentration ↓ 87% Rifampin AUC ↑ 60% | Do not coadminister. Use azithromycin in place of clarithromycin. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ clarithromycin expected ↑ 14-OH clarithromycin and rifapentine expected | Daily Rifapentine
Weekly Rifapentine
If coadministered, monitor for rifapentine toxicities and clarithromycin efficacy; perform clarithromycin and rifapentine TDM and adjust doses accordingly. | |
| Voriconazole | ↑ clarithromycin expected | Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. | |
| Dapsone* | Rifabutina | Dapsone AUC ↓ 27% to 40% | Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
| Rifampina | Dapsone concentration ↓ 7-fold to 10-fold and t1/2 ↓ from 24 hours to 11 hours | Coadministration should be avoided, if possible. Consider alternatives for dapsone. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ dapsone expected | Coadministration should be avoided, if possible. Consider alternatives for dapsone. | |
| Doxycycline | Atovaquone | See Atovaquone. | See Atovaquone. |
| Rifabutina | ↓ doxycycline possible | Monitor closely for doxycycline efficacy or consider alternative therapy. | |
| Rifampina | Doxycycline AUC ↓ 59% | Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. | |
| Rifapentinea | Daily Rifapentine
Weekly Rifapentine
| Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. | |
| Erythromycin | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Fluconazole | ↑ erythromycin possible | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Isavuconazole | ↑ erythromycin and isavuconazole possible | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Itraconazole | Itraconazole AUC ↑ 36% ↑ erythromycin possible | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Mefloquine | ↑ mefloquine possible | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Posaconazole | ↑ erythromycin expected | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Quinine | ↑ quinine expected ↑ erythromycin possible | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Rifabutina | ↓ erythromycin possible ↑ rifabutin possible | Use with caution. Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy and rifabutin toxicities; perform rifabutin TDM and adjust dose accordingly. | |
| Rifampina | ↓ erythromycin expected | Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ erythromycin expected | Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. | |
| Voriconazole | ↑ erythromycin expected | Do not coadminister. Consider azithromycin in place of erythromycin. | |
| Fluconazole* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Mefloquine | ↑ mefloquine possible | Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. | |
| Quinine | ↑ quinine expected ↑ fluconazole possible | Coadministration should be avoided, if possible. If coadministered, monitor for quinine and fluconazole toxicity. | |
| Rifabutina | Rifabutin AUC ↑ 80% ↔ fluconazole expected | Use with caution. Monitor for rifabutin toxicities. Perform rifabutin TDM; may need to decrease rifabutin dose to 150 mg/day. | |
| Rifampina | Fluconazole AUC ↓ 23% to 56% | Monitor for antifungal efficacy; may need to increase fluconazole dose. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ fluconazole expected | Monitor for antifungal efficacy; may need to increase fluconazole dose. | |
Glecaprevir/ Pibrentasvir | Rifabutina | ↓ glecaprevir and pibrentasvir possible | Coadministration should be avoided, if possible. Consider alternative agents. |
| Rifampina | Glecaprevir AUC ↓ 88% Pibrentasvir AUC ↓ 87% | Do not coadminister. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ glecaprevir and pibrentasvir expected | Do not coadminister. Consider alternative agents. | |
| TDF | TFV AUC ↑ 29% when coadministered as EFV/TDF/FTC | Use usual dose. Monitor renal function or consider TAF. | |
| TAF | ↔ TFV concentration when coadministered as EVG/c/TAF/FTC | No dose adjustment necessary | |
| Isavuconazole* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Mefloquine | ↑ mefloquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. | |
| Quinine | ↑ quinine expected ↑ isavuconazole possible | Coadministration should be avoided, if possible. If coadministered, monitor for quinine and isavuconazole toxicities. | |
| Rifabutina | ↓ isavuconazole expected ↑ rifabutin expected | Consider alternative agent(s). If alternative agents are not available, use with close monitoring for isavuconazole antifungal activity and rifabutin toxicity. Perform rifabutin TDM and adjust dose accordingly. | |
| Rifampina | Isavuconazole AUC ↓ 97% | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ isavuconazole expected | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Itraconazole* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Mefloquine | ↑ mefloquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. | |
| Quinine | ↑ quinine expected ↑ itraconazole possible | Coadministration should be avoided, if possible. If coadministered, monitor for quinine and itraconazole toxicities; perform itraconazole TDM and adjust dose accordingly. | |
| Rifabutina | Itraconazole AUC ↓ 70% ↑ rifabutin expected | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Rifampina | Itraconazole AUC ↓ 64% to 88% | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ itraconazole expected | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Linezolid* | Rifabutina | ↓ linezolid possible | Monitor for linezolid efficacy. |
| Rifampina | Linezolid AUC ↓ 32% | Monitor for linezolid efficacy. Perform linezolid TDM and adjust dose accordingly. | |
| Rifapentinea | Daily Rifapentine ↓ linezolid expected Weekly Rifapentine ↓ linezolid possible | Daily Rifapentine Monitor for linezolid efficacy. Perform linezolid TDM and adjust dose accordingly. Weekly Rifapentine Monitor for linezolid efficacy. | |
| Mefloquine* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Fluconazole | See Fluconazole. | See Fluconazole. | |
| Isavuconazole | See Isavuconazole. | See Isavuconazole. | |
| Itraconazole | See Itraconazole. | See Itraconazole. | |
| Posaconazole | ↑ mefloquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. | |
| Rifabutina | ↓ mefloquine possible | Monitor for mefloquine efficacy. | |
| Rifampina | Mefloquine AUC ↓ 68% | Do not coadminister. Use alternative antimalarial drug or rifabutin. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ mefloquine expected | Do not coadminister. Use alternative antimalarial drug or rifabutin. | |
| Voriconazole | ↑ mefloquine expected | Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. | |
| Posaconazole* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Mefloquine | See Mefloquine. | See Mefloquine. | |
| Quinine | ↑ quinine expected ↑ posaconazole possible | Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. | |
| Rifabutina | Posaconazole AUC ↓ 49% Rifabutin AUC ↑ 72% | Coadministration should be avoided, if possible. If coadministered, perform posaconazole and rifabutin TDM and adjust doses accordingly; monitor for clinical response to posaconazole and rifabutin toxicities. | |
| Rifampina | ↓ posaconazole expected | Do not coadminister when treating invasive fungal infections. If coadministered for treatment of noninvasive fungal infections, perform posaconazole TDM and adjust dose accordingly; monitor for clinical response. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ posaconazole expected | Daily Rifapentine Do not coadminister when treating invasive fungal infections. If coadministered for treatment of noninvasive fungal infections, perform posaconazole TDM and adjust dose accordingly; monitor for clinical response. Weekly Rifapentine Coadministration should be avoided, if possible. If coadministered, perform posaconazole TDM and adjust dose accordingly; monitor clinical response. | |
| Quinine* | Clarithromycin | See Clarithromycin. | See Clarithromycin. |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Fluconazole | See Fluconazole. | See Fluconazole. | |
| Itraconazole | See Itraconazole. | See Itraconazole. | |
| Posaconazole | See Posaconazole. | See Posaconazole. | |
| Rifabutina | ↓ quinine possible ↑ rifabutin possible | Monitor for quinine efficacy. Monitor for rifabutin toxicity. | |
| Rifampina | Quinine AUC ↓ 75% to 85% | Do not coadminister. | |
| Rifapentinea | Daily and Weekly Rifapentine ↓ quinine expected | Do not coadminister. | |
| Voriconazole | ↑ quinine expected | Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. | |
| Rifabutina* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Atovaquone | See Atovaquone. | See Atovaquone. | |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Caspofungin | See Caspofungin. | See Caspofungin. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Dapsone | See Dapsone. | See Dapsone. | |
| Doxycycline | See Doxycycline. | See Doxycycline. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Fluconazole | See Fluconazole. | See Fluconazole. | |
| Glecaprevir/Pibrentasvir | See Glecaprevir/Pibrentasvir. | See Glecaprevir/Pibrentasvir. | |
| Isavuconazole | See Isavuconazole. | See Isavuconazole. | |
| Itraconazole | See Itraconazole. | See Itraconazole. | |
| Linezolid | See Linezolid. | See Linezolid. | |
| Mefloquine | See Mefloquine. | See Mefloquine. | |
| Posaconazole | See Posaconazole. | See Posaconazole. | |
| Quinine | See Quinine. | See Quinine. | |
| Sofosbuvir/Velpatasvir | ↓ velpatasvir, sofosbuvir expected | Do not coadminister. | |
| TAF | ↓ TAF, TFV, TFV-DP expected ↑ TFV-DP expected versus TDF alone | If coadministered, monitor for HIV and HBV treatment efficacy. Note: Interpretation extrapolated from TAF and rifampin (see Rifampin). FDA labeling recommends not to coadminister. | |
| TDF | ↔ TDF, TFV, TFV-DP expected | No dosage adjustment necessary. | |
| Voriconazole | Voriconazole AUC ↓ 79% Rifabutin AUC ↑ 4-fold | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). Coadministration may be considered if both voriconazole and rifabutin TDM is available to guide therapy. | |
| Rifampina* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Atovaquone | See Atovaquone. | See Atovaquone. | |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Caspofungin | See Caspofungin. | See Caspofungin. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Dapsone | See Dapsone. | See Dapsone. | |
| Doxycycline | See Doxycycline. | See Doxycycline. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Fluconazole | See Fluconazole. | See Fluconazole. | |
| Glecaprevir/Pibrentasvir | See Glecaprevir/Pibrentasvir. | See Glecaprevir/Pibrentasvir. | |
| Isavuconazole | See Isavuconazole. | See Isavuconazole. | |
| Itraconazole | See Itraconazole. | See Itraconazole. | |
| Linezolid | See Linezolid. | See Linezolid. | |
| Mefloquine | See Mefloquine. | See Mefloquine. | |
| Posaconazole | See Posaconazole. | See Posaconazole. | |
| Quinine | See Quinine. | See Quinine. | |
| Sofosbuvir/Velpatasvir | Sofosbuvir AUC ↓ 72% Velpatasvir AUC ↓ 82% | Do not coadminister. | |
| TAF | TAF Plus Rifampin
Intracellular TFV-DP concentration is 4.2-fold greater than with TDF alone. | If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. | |
| TDF | TDF Plus Rifampin 600 mg Daily ↔ TFV | No dosage adjustment necessary | |
| Voriconazole | Voriconazole AUC ↓96% | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Rifapentinea* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Atovaquone | See Atovaquone. | See Atovaquone. | |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Caspofungin | See Caspofungin. | See Caspofungin. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Dapsone | See Dapsone. | See Dapsone. | |
| Doxycycline | See Doxycycline. | See Doxycycline. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Fluconazole | See Fluconazole. | See Fluconazole. | |
| Glecaprevir/Pibrentasvir | See Glecaprevir/Pibrentasvir. | See Glecaprevir/Pibrentasvir. | |
| Isavuconazole | See Isavuconazole. | See Isavuconazole. | |
| Itraconazole | See Itraconazole. | See Itraconazole. | |
| Linezolid | See Linezolid. | See Linezolid. | |
| Mefloquine | See Mefloquine. | See Mefloquine. | |
| Posaconazole | See Posaconazole. | See Posaconazole. | |
| Quinine | See Quinine. | See Quinine. | |
| TAF | Daily and Weekly Rifapentine ↓ TAF, TFV, TFV-DP possible | If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. | |
| TDF | ↔ TDF, TFV, TFV-DP expected | No dosage adjustment necessary | |
| Sofosbuvir/Velpatasvir | ↓ sofosbuvir, velpatasvir expected | Do not coadminister. | |
| Voriconazole | ↓ voriconazole expected | Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). | |
| Sofosbuvir*/ Velpatasvir | Rifabutina | See Rifabutin. | See Rifabutin. |
| Rifampina | See Rifampin. | See Rifampin. | |
| Rifapentinea | See Rifapentine. | See Rifapentine. | |
| TAF | TFV AUC ↑ 52% (when RPV/TAF/FTC given with SOF/VEL/VOX) | No dosage adjustment necessary | |
| TDF | TFV AUC ↑ 35% to 40% (when given with EVG/c/FTC or RPV/FTC) TFV AUC ↑ 81% (when given with EFV/FTC and SOF/VEL) TFV AUC ↑ 39% (when given with DRV/r/FTC and SOF/VEL/VOX) | Monitor for TDF toxicities. Consider TAF in place of TDF. | |
| Tenofovir* Alafenamide | Glecaprevir/Pibrentasvir | See Glecaprevir/Pibrentasvir. | See Glecaprevir/Pibrentasvir. |
| Rifabutina | See Rifabutin. | See Rifabutin. | |
| Rifampina | See Rifampin. | See Rifampin. | |
| Rifapentinea | See Rifapentine. | See Rifapentine. | |
| Sofosbuvir/Velpatasvir | See Sofosbuvir/Velpatasvir. | See Sofosbuvir/Velpatasvir. | |
| Tenofovir* Disoproxil Fumarate | Rifabutina | See Rifabutin. | See Rifabutin. |
| Rifampina | See Rifampin. | See Rifampin. | |
| Rifapentinea | See Rifapentine. | See Rifapentine. | |
| Glecaprevir/Pibrentasvir | See Glecaprevir/Pibrentasvir. | See Glecaprevir/Pibrentasvir. | |
| Sofosbuvir/Velpatasvir | See Sofosbuvir/Velpatasvir. | See Sofosbuvir/Velpatasvir. | |
| Voriconazole* | Artemether/Lumefantrine | See Artemether/Lumefantrine. | See Artemether/Lumefantrine. |
| Bedaquiline | See Bedaquiline. | See Bedaquiline. | |
| Chloroquine | See Chloroquine. | See Chloroquine. | |
| Clarithromycin | See Clarithromycin. | See Clarithromycin. | |
| Erythromycin | See Erythromycin. | See Erythromycin. | |
| Mefloquine | See Mefloquine. | See Mefloquine. | |
| Quinine | See Quinine. | See Quinine. | |
| Rifabutina | See Rifabutin. | See Rifabutin. | |
| Rifampina | See Rifampin. | See Rifampin. | |
| Rifapentinea | See Rifapentine. | See Rifapentine. | |
a Refer to the subsection Rifamycin-Related Induction Interactions in the Table 4 introduction above. * Drugs marked with asterisk (*) are those which are known to have assays available (for clinical and/or research purposes) within the United States and typically in Europe. When TDM is appropriate, clinicians should contact their clinical laboratory to determine assay availability and turnaround time for their institution. Key to Symbols Key: 14-OH = active metabolite of clarithromycin; AUC = area under the curve; Cmin = minimum concentration; Css = concentration at steady state; des-Rbt = desacetyl rifabutin; DHA = dihydroartemisinin; DRV/r = darunavir/ritonavir; EFV = efavirenz; EVG/c = elvitegravir/cobicistat; FDA = U.S. Food and Drug Administration; FTC = emtricitabine; HBV = hepatitis B virus; RPV = rilpivirine; SOF = sofosbuvir; t1/2 = half-life; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug monitoring; TFV= tenofovir; TFV-DP = tenofovir diphosphate; VEL = velpatasvir; VOX = voxilaprevir | |||
Download Guidelines
- Section Only PDF (259.62 KB)
- Full Guideline PDF (6.09 MB)
- Tables Only PDF (1.13 MB)